Episode Details

NurExone Biologic (TSXV: NRX) is advancing both the therapeutic and commercial sides of its exosome platform, with US-based GMP manufacturing, expansion into Mexico, commercial exosome sales, new financing and plans for a potential US listing. CEO Lior Shaltiel joins Ricki Lee to discuss the company's strategy and the milestones ahead.

In this episode, listeners will hear about:

• NurExone's US-based GMP manufacturing strategy with Made Scientific
• The commercial opportunity for exosome products through ExoTop
• Expansion into Mexico and the broader North American market
• The recent private placement and potential US cross-listing
• Key therapeutic and commercial milestones expected over the next 6–12 months

This podcast is made in partnership with NurExone Biologic. This podcast is for informational purposes only. Please do your own due diligence. For our full disclaimer, visit: https://stockhouse.com/legal/disclaimer

#NurExone #Biotechnology #Exosomes #RegenerativeMedicine #NASDAQ #BiotechStocks #Investing

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.